Ribociclib (Kisqali) prior authorization at Premera Blue Cross
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Premera Blue Cross requires prior-authorization documentation for Ribociclib (Kisqali): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Premera Blue Cross reviews Ribociclib (Kisqali) prior authorizations against its medical policy . Premera Blue Cross-specific context: BCBS licensee for Washington and Alaska (~2.4M members). Express Scripts PBM. WA OIC oversight. WA has strong mental health parity enforcement and surprise-billing protections that pre-date federal NSA.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in this class
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Premera Blue Cross's medical policy URL referenced in the cover letter
Premera Blue Cross's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- WA-specific mental health parity violations
- Step therapy via Express Scripts
- Out-of-network reductions
- Specialty drug prior auth
Ribociclib (Kisqali)-specific denial patterns and context
Across payers (not just Premera Blue Cross), Ribociclib (Kisqali)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring palbociclib first within CDK4/6 class
- QTc monitoring requirement not documented
- Early breast cancer (adjuvant) indication denial despite FDA approval September 2024
- Combination partner formulary restriction
Brand: Kisqali. CDK4/6 inhibitor. MONALEESA trial series showed overall survival benefit. FDA-approved for early-stage HR+/HER2- breast cancer (adjuvant) September 2024 based on NATALEE — appeals frequently cite this.
Manufacturer patient-assistance program: Novartis Patient Assistance Foundation — relevant when a Premera Blue Cross denial sticks and the patient needs bridge access while appealing.
How Premera Blue Cross approaches Specialty pharmacy drugs PAs
Premera Blue Cross's Specialty pharmacy drugs reviewer typically anchors Ribociclib prior-auth decisions on step therapy via express scripts and specialty drug prior auth. Pharmacy-benefit review for Ribociclib at Premera Blue Cross is routed through Express Scripts. The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Premera Blue Cross routes specialty-pharmacy denials through a separate appeal queue from medical-benefit denials — verify the appeal goes to the correct queue or it can be administratively denied for "wrong path". Premera Blue Cross is domiciled in WA, so unresolved appeals escalate to the WA insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). BCBS licensee for Washington and Alaska (~2.
If the PA is denied
Premera Blue Cross gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.premera.com/wa/provider) with the same packet plus a peer-reviewed citation supporting Ribociclib (Kisqali)for the patient's indication.
Contact Premera Blue Cross
- Provider portal: https://www.premera.com/wa/provider
Frequently asked questions
What documentation does Premera Blue Cross need for Ribociclib (Kisqali) prior auth?
Premera Blue Cross's typical PA packet for Ribociclib (Kisqali): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis.
What's the turnaround time at Premera Blue Cross?
Standard Ribociclib (Kisqali) PA decisions at Premera Blue Cross: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Premera Blue Cross most often reject Ribociclib (Kisqali) for?
Across Premera Blue Cross's book the common rejection patterns include: WA-specific mental health parity violations; Step therapy via Express Scripts; Out-of-network reductions. For Ribociclib (Kisqali) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Which specialty pharmacy will Premera Blue Cross require for Ribociclib?
Premera Blue Cross contracts with a specific specialty-pharmacy network — using an out-of-network specialty pharmacy is a common denial cause that is administrative rather than medical-necessity. Call the prior-auth line on the back of the member card to confirm the in-network specialty pharmacy for Ribociclib before submission. Note that REMS-restricted Ribociclib variants (where applicable) further narrow the in-network pharmacy list. Pharmacy-benefit handling is routed through Express Scripts. External-review escalation for Premera Blue Cross fully-insured policies sits with the WA insurance department.
How do I prep for a peer-to-peer with Premera Blue Cross on Ribociclib (Kisqali)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the Ribociclib (Kisqali) PA packet
Open ApprovalHelp — generate a Ribociclib (Kisqali) prior-auth packet tailored to Premera Blue Cross's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com